Wednesday, July 27, 2016 4:38:11 PM
Milestones and PR/marketing/professional conferences exposure will cause pps to rise. How far depends on the trading volume.
The market already knows what this type of product can do via ISRG. There's built in value with each milestone and progress across the timeline. It will also be beneficial when/if ever the company will share publicly regarding documentation of medical procedures.
I expect the pps to double from now to end of this year - depending on published progress. Then double again with passing the final CE audit sometime 2nd half of 2017. IMO.
Call it about - $3.00 pps 3-4Q '17. That's not a bad investment, but not why I'm invested. I see much, much bigger numbers late Q1 - early Q2 2018. 18-20 months.
Regards,
BK
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM